The poor prognosis of acute megakaryoblastic leukaemia (AMKL) means there is a need to develop novel therapeutic methods to treat this condition. It was recently shown that inducing megakaryoblasts to undergo terminal differentiation is effective as a treatment for AMKL. This encouraged us to identify a compound that induces megakaryocyte differentiation, which could then act as a potent anti-leukaemia agent.
Introduction
Acute megakaryoblastic leukaemia (AMKL) is a rare and heterogeneous subtype of acute myeloid leukaemia (AML) (FAB M7 AML) with poor prognosis that accounts for approximately 10% of paediatric AML and 1% of adult AML (Athale et al., 2001; Oki et al., 2006; Gruber et al., 2012) . Paediatric AMKL is divided into two major molecular subtypes: trisomy 21 in Down syndrome AMKL (DS-AMKL) present with acquired GATA-binding protein 1 mutations and non-Down syndrome patients (non-DS-AMKL) associated with the expression of the OTT-MAL and CBFA2T3-GLIS2 fusion protein (Mercher et al., 2001; 2002; Gruber et al., 2012) . Although high-intensity chemotherapy is used to treat this condition clinically, the survival of AMKL patients is still dismal. In particular, the non-DS-AMKL patients have a very poor prognosis with the majority of patients relapsing within 1 year (Malinge et al., 2009) .
Based on the features of the AML cells, differentiation therapy is a potential chemotherapeutic approach for targeting specific myeloid leukaemia cells (Bruserud, 2000; Petrie et al., 2009; Krause and Crispino, 2013) . All-trans retinoic acid (ATRA) significantly improved the chemotherapeutic outcome of patients with acute promyelocytic leukaemia (APL), which is a successful example of differentiation therapy (Marchwicka et al., 2014; Coombs et al., 2015) . Leukaemic blasts from AMKL patients are hyperproliferative and fail to terminally differentiate into mature megakaryocytes. This gives researchers hope that they will eventually develop ways to force the AMKL cells to exit the proliferative cell cycle and undergo terminal differentiation (Wen et al., 2012) . A series of studies using agents that specifically promote the terminal differentiation of leukaemia cells into megakaryocytes are in development (Ojima et al., 2013; Liu et al., 2014; Han et al., 2015) . Of note, it has been demonstrated that autophagy is an important event for megakaryocytic differentiation of the human leukaemia cell line K562 (Colosetti et al., 2009; Cao et al., 2015) , which has been extensively used as a model to study megakaryocyte differentiation. Reports have documented that agents that induce differentiation, such as rapamycin, ATRA and As 2 O 3 , all stimulated the autophagy-dependent proteolysis of fusion oncoproteins, including promyelocytic leukaemia-retinoic acid receptor α in APL cells and BCR-ABL in chronic myelogenous leukaemia cells (Goussetis et al., 2010 (Goussetis et al., , 2012 (Goussetis et al., , 2013 Lallemand-Breitenbach et al., 2012; Elzinga et al., 2013) . Thus, we speculated that autophagy induction could be an effective anti-leukaemia strategy (Carew et al., 2007; Kamitsuji et al., 2008) .
Tetrandrine [(1b)-6,6 0 ,7,12-tetramethoxy-2,2 0 -dimethylberbaman] is a natural product from the bisbenzylisoquinoline alkaloid family that was originally isolated from the roots of the Chinese herb Stephania tetrandra S. Moore (Schiff, 1987) . Recently, several studies demonstrated that tetrandrine has pharmacological potential in cancer therapy with multiple bioactivities (Liu et al., 2016) . We previously showed that tetrandrine, either alone or in combination with other drugs, exhibited antitumour effects against cancer cells (Gong et al., 2012; Wan et al., 2013; Mei et al., 2015) . Remarkably, we demonstrated that tetrandrine is an effective, broad-spectrum inducer of autophagy and is more potent than rapamycin at activating autophagy .
In this study, we specifically analysed the effects of tetrandrine on the induction of megakaryocytic differentiation in leukaemia cells. Our data suggest that treating these leukaemia cells with tetrandrine inhibited cell proliferation and induced the cells to differentiate into the megakaryocytic lineage in vitro and in vivo, and this effect was mediated by the activation of autophagy. The ROS/Notch1/Akt signalling cascade may be involved in this mechanism. These findings show that tetrandrine has potent anti-leukaemia activity in vitro and in vivo, which indicates tetrandrine has the potential to be developed as a differentiation-inducing agent and may be a novel chemotherapeutic strategy for AMKL.
Methods

Reagents and antibodies
Tetrandrine was purchased from Shanghai Ronghe Medical, Inc (Shanghai, China) and dissolved in DMSO as a stock solution before use. 3-Methyladenine (3-MA), chloroquine (CQ) and N-acetyl-L-cysteine (NAC) were purchased from Sigma (St. Louis, MO, USA). DCFH-DA was obtained from Invitrogen (Carlsbad, CA, USA). DAPT was obtained from Selleck (Shanghai, China). Acridine orange (AO), propidium iodide (PI), GAPDH antibody and HRP-conjugated secondary antibodies were purchased from Beyotime (Nantong, China). CD41-PE was obtained from BD Biosciences (San Jose, USA). Other antibodies were obtained from the following sources respectively: p27kip1, PARP, HES1 and Notch1 were acquired from Cell Signaling Technologies (Beverly, MA, USA), and p62 and p21 were acquired from Proteintech Group Inc (Chicago, IL, USA). 
Cell lines and cell culture
Western blot analysis
After being subjected to the different treatments, cells were harvested and lysed in 1% SDS on ice; then the cell lysates were heated at 98°C for 20 min. Lysates were clarified by centrifugation at 12 000× g for 15 min. The supernatant was collected, and the protein concentration was determined by the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). Equal amounts of protein from each sample were separated on SDS-PAGE gels and transferred to PVDF membranes (Millipore, Billerica, MA, USA) and blocked for 1 h with 5% non-fat milk (Bio-Rad, Hercules, CA, USA) in Tris-buffered saline with 0.1% Tween 20 (TBST) at room temperature. Membranes were incubated with specific primary antibodies overnight at 4°C. The membranes were then washed with TBST three times (10 min every time) and incubated for 1 h with HRP-conjugated secondary antibodies at room temperature. After being washed with TBST, signals were visualized in the samples by chemiluminescent detection using an HRP substrate (Millipore). GAPDH was probed to ensure equal protein loading.
Cell proliferation and cell viability analysis
Cell proliferation was measured by counting the total number of cells. Cell viability was observed by the trypan blue dye exclusion assay. Cells were plated on 96-well plates and incubated with various concentrations of tetrandrine for the times indicated and then cells with or without trypan blue staining were counted using a haemocytometer.
Cell cycle analysis
After treatment, cells were harvested and washed with PBS and fixed with 70% ethanol overnight at 4°C. The fixed cells were centrifuged at 800× g, 25°C for 5 min, the supernatant was removed and the cells were washed with PBS and then stained with 4 μL of 10 mg·mL À1 PI and 10 μL of 1 mg·mL À1 RNase in 400 μL PBS followed by incubation in the dark for 30 min. Stained cells were assessed on a flow cytometer (Beckman, Indianapolis, CA, USA). The results were analysed by the FlowJo software (Tree Star, San Carlos, CA, USA).
Apoptosis assay
Treated cells were washed with PBS, resuspended in binding buffer and stained with Annexin V-FITC and PI for 15 min according to the kit protocol from BD Biosciences. Annexin V-FITC and PI fluorescence were estimated by use of a flow cytometer (Beckman).
Acridine orange staining assays
Cells were stained with acridine orange for the detection and quantification of autophagy, whihc was measured by a fluorescent microscope and flow cytometry. After treatment, cells were collected, and the cell suspension incubated with 1 μg·mL À1 acridine orange dye in serum-free medium for 20 min. Cells were washed with PBS, resuspended in 0.4 mL PBS and quantified by flow cytometry (Beckman). Also, the fluorescence of acridine orange was viewed under a fluorescent microscope (Leica Microsystems GmbH, Wetzlar, Germany); the cytoplasm and nucleus of the stained cells fluoresced bright green, whereas the acidic autophagic vacuoles fluoresced bright orange red. The percentage of cells with orange red puncta was used to quantify the percentage of autophagic cells. CRISPR/Cas9 KO system ATG7-knockout (KO) K562 cells were established using the CRISPR/Cas9 system according to a standard protocol. pST1374-N-NLS-flag-linker-Cas9-BSD and pGL3-U6-gRNApuromycin mut Bsa1 ACCG vector were kindly provided by Xiaodong Zhang (Wuhan University, China). Briefly, sgRNA was generated and cloned into pGL3-U6-gRNA-puromycin mut Bsa1 ACCG vector. Cas9 and sgRNA vectors were cotransfected into K562 cells for 24 h. Subsequently, cells were selected by 2 μg·mL À1 puromycin and 20 μg·mL À1 blasticidin for another 24 h. Then K562 cells were seeded onto 96-well plates for monoclonalization. About 3 weeks later, ATG7 protein expression of the cell clones was detected by Western blotting. Two pairs of small guide RNA (sgRNA) for ATG7 KO were used, and the primer sequences were sgRNA1: 5 0 -AGAAGTACCACTTCTACTAT-3 0 , sgRNA2: 5 0 -ACCGTCCTTCTTAGAAGACTTGAC-3 0 .
Differentiation analysis
Detection of glucose uptake
2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl) amino)-2-deoxyglucose (2-NBDG), a fluorescently labelled deoxyglucose analogue (Cayman Chemical, Michigan, USA), was used as a probe for detecting cellular glucose uptake; the assay was conducted according to the manufacturer's instructions. Briefly, after treatment, the cells were washed twice and preincubated in glucose-free culture medium for 2 h and then 2-NBDG was added and the samples were incubated for 20 min. The cells were washed twice prior to fluorescence detection using flow cytometry.
Quantitative real-time PCR
Total RNA was extracted from tetrandrine-treated and control cells using an RNeasy Mini Kit (Invitrogen). cDNA was synthesized from RNA with random hexamer primers using a SuperScript III kit (Invitrogen). Quantitative real-time PCR was performed using LightCycler FastStart DNA Master SYBR Green I (Roche) as specified by the manufacturer. 
Measurement of ROS accumulation
The intracellular ROS levels were detected using the DCFH-DA probe by flow cytometry. Briefly, after treatment with tetrandrine for the indicated time intervals, the cells were harvested and washed twice with PBS, incubated with DCFH-DA in PBS at 37°C for 20 min, washed twice with PBS and analysed by flow cytometry. The data were processed using the FlowJo software (Tree Star).
Healthy haematopoietic stem cell study
For the healthy haematopoietic stem cell study, fetal livers from E12.5 ICR mice were dissected, the liver tissue was passed through a 22 gauge needle to obtain a single cell suspension. After spinning down the cells at 800× g, resuspending them in cell lysis buffer and incubating at 37°C for 5 min, lysates were washed with PBS, filtered through 100 μm cell strainer and then cultured in expansion media (RPMI 1640 with 10% FBS, 10 ng·mL À1 IL-3, 10-ng·mL À1 IL-6 and 100 ng·mL À1 stem cell factor). To induce the cells to differentiate, cells were cultured in differentiation media (RPMI 1640 with 10% FBS, 10 ng·mL À1 thrombopoietin and 10 ng·mL À1 stem cell factor) for 4 days.
In vivo studies
All of the animal protocols in this study were approved by the Animal Care and Use Committee of the Laboratory Animal Centre of Wuhan University and conform to the Guidelines for the Care and Use of Laboratory Animals prepared by the National Academy of Sciences and published by the National Institutes of Health. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . For the tumour xenograft assay, the K562 cells were suspended at 1 × 10 7 cells per 0.2 mL of PBS. Five-to sixweek-old female nude mice were purchased from the Model Animal Research Centre (Changsha, China). All mice were given s.c. injections of 0.2 mL of this suspension in the right flank. The tumour growth and body weights of the mice were monitored every day. Fourteen days later, the tumours were approximately 50 mm 3 ; the tumour-bearing mice were then randomly grouped into two experimental groups. tetrandrine-treated group. After 15 days of treatment the mice were killed, and the bone marrow, liver, lung and spleen were collected, and pathological sections prepared and stained with haematoxylin-eosin (HE). An additional three groups (seven mice per group) were administered the same intragastric treatment for the survival experiment. The survival of the mice was monitored from the first day of irradiation until death. The mice were killed when they became moribund at 60 days, and all surviving mice were killed.
Statistical analysis
Student's two-tailed t-tests were performed to calculate P values unless otherwise specified. Error bars represent the SD. P < 0.05 was considered statistically significant. The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) .
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 (Alexander et al., 2015a,b,c) .
Results
Tetrandrine inhibits the proliferation and facilitates the megakaryocytic differentiation of leukaemic cells
To investigate the effect of tetrandrine on leukaemia cells, we stimulated four different leukaemic cell lines with tetrandrine. The results showed that tetrandrine induced a dose-dependent decrease in the number of cells ( Figure 1A ), but had almost no effect on cell viability at a concentration of approximately 2 μM in all of the leukaemic cell lines tested ( Figure 1B ). These results indicated that lower concentrations of (≤2 μM) tetrandrine inhibit the proliferation of leukaemic cells, but do not cause cell death. Next, investigation of the leukaemic cells treated with tetrandrine for 48 h showed that the cell cycle was significantly arrested at G 0 /G 1 phase ( Figure 1C ). The protein levels of the cyclin-dependent kinase inhibitors p21 and p27 were up-regulated in a timeand dose-dependent manner ( Figure 1D ). Importantly, the flow cytometry and Western blot analysis showed the CD41 ( Figure 1E and Supporting Information Figure S1A , B) as well as CD61 and CD42 (Supporting Information Figure  S1C ) levels were up-regulated, which indicates megakaryocytic differentiation occurred. Furthermore, we observed marked megakaryocytic differentiation, as demonstrated by the morphological modifications in the unstained and Wright-Giemsa-stained leukaemic cells that had been treated with tetrandrine for 4 days, including an increase in the sizes of both the cell and nucleus and an accumulation of large vacuoles ( Figure 1F ). Moreover, tetrandrine promoted CD41 expression and enhanced the percentage of cells with ploidy ≥4N on day 4 and ploidy >4N on day 6 in K562 cells in the presence of tetradecanoylphorbol acetate (TPA), which indicates that tetrandrine can enhance TPA-induced terminal megakaryocytic differentiation (Supporting Information Figure S1D , E). These results show that tetrandrine can inhibit proliferation and facilitate the megakaryocytic differentiation of leukaemic cells.
Low dose of tetrandrine induces autophagy of leukaemic cells
Previous work in our laboratory indicated that tetrandrine is a potent, broad-spectrum stimulator of autophagy that has effects on a variety of cell lines. To identify the effects of tetrandrine on autophagy in leukaemic cells, Western blot analysis showed that tetrandrine induced a dose-and time-dependent increase in LC3-II levels, accompanied by a change in the levels of the p62 protein; however, there was almost no effect on PARP when the leukaemia cells were treated with (≤2 μM) tetrandrine for 24 h ( Figure 2A and Supporting Information S2A, B). Further analysis by use of acridine orange staining ( Figure 2B , C) and the GFP-LC3
Figure 1
Tetrandrine inhibits proliferation and facilitates the megakaryocytic differentiation of leukaemic cells. The data are representative of the values from at least five independent experiments and are presented as mean ±SD; significance was determined using t-tests (*P 
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fluorescent puncta ( Figure 2D ) to detect cellular autophagy supported the Western blot results. By using pEGFP-mRFP tandem fluorescent-tagged LC3, we clearly showed that after 48 h treatment, some tetrandrine-treated cells showed only mRFP-LC3 dots, and all tetrandrine combine chloroquine-treated cells showed both mRFP and GFP-LC3 dots, which indicated that tetrandrine induced autophagy flux (Supporting Information Figure S2C ). In particular, we observed that mitophagy occurred in the GFP-LC3-expressing K562 cells that had been labelled with the MitoTracker Red dye after treatment with 2 μM tetrandrine for 24 h, since green light points of GFP-LC3 and red light points of MitoTracker had been co-located; this was observed under a confocal microscopy ( Figure 2E ). Furthermore, analysis of the results from double staining with PI and Annexin-V-FITC detected by flow cytometry and apoptosis-associated protein evaluated by Western blotting demonstrated that a high dose of tetrandrine (>2 μM) significantly induced leukaemic cell apoptosis ( Figure 2F , G).
Therefore, we conclude that a low dose of tetrandrine induces autophagy and high dose of tetrandrine induces apoptosis of leukaemia cells.
Intracellular ROS generation is involved in tetrandrine-induced cellular autophagy and differentiation
Chemotherapy is one of the multiple forms of cellular stress that stimulates oxidative stress and the production of ROS (Sawayama et al., 2008) . As expected, we showed that the intracellular ROS levels were significantly increased in the tetrandrine-treated leukaemic cells in time-and dosedependent manner ( Figure 3A ). This ROS accumulation can be effectively eliminated by the antioxidants N-acetyl-L-cysteine (NAC) and tiron ( Figure 3B and Supporting Information Figure S3A ). Notably, we found that NAC significantly inhibited the increased LC3-II and p62 expression and the intensity of the acridine orange red staining in the tetrandrine- Anti-AMKL effect of tetrandrine BJP treated leukaemic cells ( Figure 3C and Supporting Information Figure S3B ). Furthermore, the up-regulation of CD41 by tetrandrine was also reduced after NAC and tiron treatment ( Figure 3D and Supporting Information Figure S3C ). In addition, the tetrandrine-increased cell cycle arrest and increased p27 expression were consistently blocked by NAC ( Figure 3E and Supporting Information Figure S3D ). Because the major cellular source of ROS generation is the mitochondrial oxidative metabolism, which may affect glucose uptake (Kania et al., 2015) , we evaluated the effects of tetrandrine on the mitochondrial membrane potential and glucose uptake in the K562 cells. The results showed that both the mitochondrial membrane potential and glucose uptake were decreased after treatment with tetrandrine, and this could be restored by NAC treatment (Figure 3F, G) . Thus, these results suggest that ROS activation may effectively affect autophagy, proliferation, megakaryocytic differentiation and metabolism in leukaemia cells in response to tetrandrine treatment.
Autophagy is an important event in tetrandrine-induced differentiation
There is accumulating evidence demonstrating that autophagy is an important event in megakaryocytic differentiation and the autophagy-related gene ATG7 shows a relatively low expression in AML patients according to the oncomine database (Supporting Information Figure S4A ). Meanwhile, we have also found that the cells with acridine orange redstained acidic vesicular organelles (AVOs) have increased 
BJP T Liu et al.
CD41 expression ( Figure 4A ). To determine whether autophagy induction is involved in tetrandrine-induced megakaryocytic differentiation, the autophagy inhibitors 3-MA and chloroquine were used to inhibit autophagy. LC3-II expression and acridine orange red staining were analysed ( Figure 4B and Supporting Information Figure S4B , C). After the inhibition of autophagy, the tetrandrine-induced CD41 up-regulation was partially decreased ( Figure 4C , D and Supporting Information Figure S4D ). To further address the role of autophagy in tetrandrine-induced differentiation, we genetically inhibited autophagy by knocking out ATG7 in the K562 cells and selected four monoclonal mutant cell lines for gene sequence analysis and autophagy detection (Supporting Information Figure S4E , F and Figure 4E ). We could not observe tetrandrine-induced mitophagy in the ATG7-KO K562 cells ( Figure 4F ). Notably, consistent with the effect of the autophagy inhibitors, there were almost no changes in the CD41 levels or the morphology, indicating that megakaryocytic differentiation had not occurred in tetrandrine-treated ATG7-KO K562 cells ( Figure 4G and Supporting Information Figure S4G ). However, the tetrandrine-induced anti-proliferation effect, cell cycle arrest and the ROS accumulation were still observed in the ATG7-KO K562 cells (Supporting Information Figure S4H and Figure 4H , I). These data suggest that autophagy indeed plays a critical role in tetrandrine-induced megakaryocytic differentiation.
The activation of Notch1 signalling is involved in the effects of tetrandrine on the proliferation, autophagy and differentiation of leukaemic cells Anti-AMKL effect of tetrandrine BJP database shows that despite the relatively high levels of the Notch1 receptor in AML patient samples, the Notch target gene HES1 was expressed at low levels (Supporting Information Figure S5A ), suggesting that the Notch pathway was present but not activated. We demonstrated that the production of the Notch1 intracellular domain (NICD) and HES1 expression were increased in the tetrandrinetreated cells in dose-and time-dependent manners ( Figure 5A ), which were inhibited by DAPT, resulting in the inhibition of tetrandrine-induced autophagy and differentiation ( Figure 5B , C and Supporting Information Figure S5B ).
To further confirm whether the activated Notch1 pathway is associated with the anti-leukaemic effect of tetrandrine, we used a shRNA against the Notch1 gene to interfere with this pathway ( Figure 5D and Supporting Information Figure  S5C , D). In accord with the DAPT treatment, the K562 cells that expressed shNotch1 exhibited a significantly reduced autophagy, differentiation and anti-proliferation effect in response to tetrandrine, accompanied by changes in the p21 and p27 protein levels ( Figure 5D -F and Supporting Information Figure S5E , F). However, Notch1 knockdown had no effect on the increased ROS levels induced by
Figure 3
Intracellular ROS production is involved in the tetrandrine-induced effects on cellular proliferation, autophagy and differentiation. The data are representative of the values from at least five independent experiments and are presented as mean ±SD; significance was determined using t tests (*P <0.05). (A) The intracellular ROS levels of the leukaemia cells were detected by flow cytometry after the cells had been treated with 2 μM tetrandrine for different amounts of time or with different doses (0, 1, 2 μM) of tetrandrine for 24 h. (B) The cells were pretreated with 10 mM NAC for 1 h, and then treated with DMSO or 2 μM tetrandrine. The intracellular ROS levels were measured by flow cytometry and (C) the LC3 and p62 levels in the leukaemia cells were analysis by Western blots after 24 hours of treatment. (D) CD41 expression was measured by flow cytometry after 4 days of treatment. (E) After 48 h of treatment, the cells were stained with PI and the cell cycle was assessed on a flow cytometer. (F) After the indicated treatments, the glucose uptake levels and (G) mitochondrial membrane potential of the K562 cells were detected by staining the cells with 2-NBDG and Rho123, followed by flow cytometry, respectively.
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tetrandrine ( Figure 5G ). The NAC and tiron can inhibit the increase in NICD and HES1 levels induced by tetrandrine ( Figure 5H and Supporting Information Figure S5G ). Collectively, Notch1 activation is the downstream signalling pathway from ROS and is involved in tetrandrine-induced proliferation inhibition, autophagy and differentiation in leukaemia cells.
The tetrandrine-induced autophagy and differentiation of leukaemic cells is dependent on Akt signalling
Numerous reports have shown the activation of the Akt pathway is essential for normal megakaryocytic differentiation from common myeloid progenitors (Cornejo et al., 2011).
Next, we examined whether Akt signalling was involved in the tetrandrine-induced differentiation of leukaemia cells. Firstly, we found that the p-Akt levels were dose dependently up-regulated by tetrandrine in the leukaemia cells at the early time points ( Figure 6A ). The inhibition of Akt by the PI3K/Akt inhibitor wortmannin reduced the LC3-II levels, the number of cells with AO red-stained AVOs ( Figure 6B and Supporting Information Figure S6A ), and reduced the CD41 expression in the tetrandrine-treated K562 cells ( Figure 6C ). To further investigate the role of Akt in the effects of tetrandrine, a constitutively active form of Akt (myristoylated, myr-Akt) was transfected into the K562 and 6133 cells. In both of these cell lines, myr-Akt increased the expression of LC3-II and CD41 ( Figure 6D , E and Supporting Information Figure S6B ). In addition, Anti-AMKL effect of tetrandrine BJP wortmannin also reduced the LC3-II and CD41 levels in the cells transfected with myr-Akt (Supporting Information Figure  S6C , D). Finally, we determined whether Akt was involved in the effects of tetrandrine on ROS levels and Notch1 signalling. Figure 6F , G shows that the inhibition of Akt by wortmannin did not affect ROS activation, but the elimination of ROS by NAC resulted in a decrease in the p-Akt levels in the presence of tetrandrine. Moreover, when the K562 cells were treated with wortmannin or myr-Akt, there was no impact on the increased NICD levels ( Figure 6H ). However, DAPT and shNotch1 decreased the up-regulation of the p-Akt levels ( Figure 6I ). Thus, the ROS/Notch1 pathway that mediates tetrandrine-induced autophagy and differentiation in leukaemia cells is dependent on Akt signalling.
Figure 4
Autophagy is an important event in tetrandrine-induced differentiation. The data are representative of the values from at least five independent experiments and are presented as mean ±SD; significance was determined using t-tests (*P Tetrandrine, 2μM, has no apparent toxicity or effects on megakaryocytic differentiation in healthy haematopoietic stem cells
Since megakaryocytic leukaemia is rare, studying primary human leukaemia cells is a challenge. The effect of tetrandrine on mouse healthy haematopoietic stem cells has been studied here. As shown in Figure 7 , the results showed that 2 μΜ terandrine has no apparent toxic effects on cell viability and megakaryocytic differentiation, even though it triggered autophagy in mouse healthy haematopoietic stem cells, which is consistent with our previous findings. In addition, we found that tetrandrine has no significant effects on colony formation and CD41 expression of human cord blood mononuclear cells that contain CD34 + cells (Supporting Information Figure S7A , B).
Tetrandrine prolongs the survival of the 6133 mouse megakaryoblastic leukaemia model and repressed the growth of K562 tumour xenografts in athymic nude mice
The anti-leukaemic effect of tetrandrine was also examined in mice with 6133 megakaryoblastic leukaemia. Mice with 6133 cell-induced megakaryoblastic leukaemia were treated with vehicle, 30 mg·kg À1 tetrandrine or 60 mg·kg À1 tetrandrine for 15 days, beginning at day 5 after the bone marrow transplant (BMT). Remarkably, the tetrandrine treatment significantly prolonged the survival of the mice with AMKL ( Figure 8A ). In addition, compared with the healthy control and vehicle-treated mice, the HE staining of the liver, lung and spleen tissue from the tetrandrine-treated mice with AMKL displayed catabatic metastasis and the infiltration of leukaemia cells ( Figure 8B ). To further evaluate the effect of tetrandrine on leukaemia cells in vivo, we established s.c. tumour xenograft models in athymic nude mice using the K562 and ATG7-KO K562 cells. Consistent with our in vitro findings, the tetrandrine treatment reduced the K562 tumour growth, reducing the tumour volume and weight, but only had a weak effect on the ATG7-KO K562 tumours ( Figure 8C, D) . Additionally, the immunohistochemistry analyses revealed that tetrandrine facilitated differentiation and Notch1 activation in vivo. However, the ATG7-KO K562 cells did not show a significant change in CD41 levels, although the Notch1 levels were increased in the tetrandrine-treated tumour tissue samples, which confirmed that autophagy is an important event in the differentiation Anti-AMKL effect of tetrandrine BJP
Figure 5
Activation of Notch1 signalling is involved in tetrandrine-induced proliferation inhibition, autophagy and differentiation of leukaemic cells. The data are representative of the values from at least five independent experiments and are presented as mean±SD; significance was determined using t-tests (*P < 0.05). (A) Western blot analysis of the NICD and HES1 proteins in K562 cells after tetrandrine (0-2.5 μM) treatment for 24 h or 2 μM tetrandrine treatment for 0-48 h. (B) The levels of the NICD, HES1 and LC3-II proteins were assessed by Western blots after the cells had been preincubated with 10 μM DAPT for 1 h and then treated with DMSO or 2 μM tetrandrine for 24 h, and (C) after 4 days of treatment, the CD41 levels in the K562 cells were detected by flow cytometry. (D) After 24 h of treatment with DMSO or 2 μM tetrandrine, the levels of the NICD, HES1, LC3-II and p62 proteins in the K562 shNC and K562 shNotch1 cells were detected by Western blotting. (E) The CD41-PE levels were detected by flow cytometry after 4 days of treatment. (F) After a 24 h treatment with DMSO or 2 μM tetrandrine, the K562 shNC and K562 shNotch1 cells were stained with PI to detect the cell cycle by flow cytometry. (G) The K562 shNC and K562 shNotch1 cells were treated with DMSO or 2 μM tetrandrine for 24 h. The intracellular ROS levels were detected by flow cytometry. (H) Western blot analysis of the NICD and HES1 levels in the leukaemia cells that had been pretreated with 10 mM NAC for 1 h and then treated with DMSO or 2 μM tetrandrine for 24 h.
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of K562 cells ( Figure 8E) . Furthermore, the levels of the lipid peroxidation product malondialdehyde, which was used as a presumptive measure of the ROS levels, were increased in both the K562 and ATG7-KO K562 tumour tissues following tetrandrine treatment ( Figure 8F ). Together, these results suggest that tetrandrine has an anti-leukaemic effect in vivo.
Discussion
Natural products have garnered increasing attention in the chemotherapy drug discovery field because they are biologically compatible and have high therapeutic effects. Tetrandrine is a natural product that was isolated from the Chinese plant S. tetrandra S. Moore. In this study, we found
Figure 6
The activation of Akt signalling is involved in tetrandrine-induced autophagy and differentiation of leukaemic cells. The data are representative of the values from at least five independent experiments and are presented as mean±SD; significance was determined using t-tests (*P <0.05). (A) Western blot analysis of the levels of the p-Akt and total Akt (T-Akt) proteins in the leukaemia cells after a 0-2.5 μM tetrandrine treatment for 24 h or a 2 μM tetrandrine treatment for 0-24 h. (B) The levels of the p-Akt, T-Akt and LC3-II proteins were assessed by Western blotting after the cells were preincubated with wortmannin for 1 h and then treated with DMSO or 2 μM tetrandrine for 10 h. (C) The CD41 levels in the leukaemia cells were detected by flow cytometry after 4 days of treatment. (D) The K562 and 6133 cells were transfected with the vector and Akt-CA plasmid and then treated with DMSO or 2μM tetrandrine. The levels of the p-Akt, T-Akt and LC3-II proteins were assessed by Western blotting after 10 h of treatment and (E) the CD41 levels were detected by flow cytometry after 4 days of treatment. (F) The intracellular ROS levels were detected by flow cytometry after the cells had been preincubated with wortmannin for 1 h and then treated with DMSO or 2 μM tetrandrine for 24 h. (G) After a 1 h pretreatment with 10 mM NAC and a subsequent treatment with DMSO or 2μM tetrandrine for 10 h, the levels of the p-Akt and T-Akt proteins in the K562 cells were analysed by Western blotting. (H) The levels of the NICD protein were assessed by Western blotting using the proteins from the K562 cells that had been preincubated with wortmannin for 1 h and then treated with DMSO or 2μM tetrandrine for 24 h, or the proteins from the K562 Akt-CA cells that had been treated with DMSO or 2μM tetrandrine for 24 h. (I) Western blot analysis of the p-Akt protein levels in the cells that had been preincubated with 10μM DAPT for 1 h and then treated with DMSO or 2 μM tetrandrine for 24 h, or in the K562 shNC and K562 shNotch1 cells that had been treated with DMSO or 2 μM tetrandrine for 10 h.
that tetrandrine induced autophagy in leukaemia cells. In addition, a low-dose of tetrandrine (≤2 μM) inhibited cell proliferation, without a marked loss of viability, but a high-dose tetrandrine (>2 μM) treatment significantly increased the apoptosis of the leukaemia cells. Furthermore, Supporting Information Figure S2D -F shows that the inhibition of tetrandrine-induced autophagy by either chloroquine or by KO of the ATG7 can potentiate the synergistic anti-leukaemia properties of tetrandrine by promoting apoptosis. This indicates that tetrandrine, either alone or in combination with other autophagy inhibitors, may be a therapeutic strategy for treating leukaemia. Previous studies have revealed that proliferating cells have an anabolic metabolism, while differentiated cells utilize a catabolic metabolism (Sardina et al., 2010) . ROS are mitochondrial metabolites and have been proven to be important activators of various cellular activities (Filomeni et al., 2015) , including cellular differentiation, and several reports showed that ROS were required for the differentiation of cells of the megakaryocytic lineage (Eliades et al., 2012; Nurhayati et al., 2014) . We consistently observed metabolic changes in the tetrandrine-treated leukaemia cells and demonstrated that ROS are involved in tetrandrine-induced megakaryocytic differentiation (Figure 3 ). To our knowledge, autophagy is triggered by numerous stresses, such as nutrient starvation, hypoxia, bacterial and viral infection or chemicals, and is regulated by multiple molecular signalling pathways (Rabinowitz and White, 2010; Scherz-Shouval and Elazar, 2011; Luo et al., 2016) . We also found that ROS have a key role in tetrandrine-induced autophagy in leukaemia cells, but autophagy had almost no effect on the tetrandrine-mediated metabolic changes (Supporting Information Figure S3E , F and Figure 4I ). In addition, the ROS-dependent stimulation of Notch1 and Akt signalling contributed to tetrandrine-induced autophagy. Nevertheless, when tetrandrine-induced autophagy was inhibited, there was no effect on the activation of the Notch1 signalling pathway (Supporting Information Figure S5H ).
Inhibiting Notch1 signalling is a therapeutic target in acute T-lymphoblastic leukaemia (Palomero and Ferrando, 2008) . However, whether Notch1 is oncogenic or tumoursuppressive in AML is still controversial (Lobry et al., 2014) . Some reports suggest that activation of Notch signalling in AML cells led to growth arrest, apoptosis and differentiation (Chadwick et al., 2008; Roy et al., 2012; Kannan et al., 2013; Lobry et al., 2013) , whereas some others indicate the reverse effects (Mercher et al., 2009) . Here in our system, our data clearly indicate that Notch1 activation is a crucial signalling Our BMT model mice that received vehicle treatment succumbed to leukaemia more rapidly than the tetrandrine-treated group, indicating that tetrandrine prolonged the survival of the mice with AMKL, but did not completely stop the progression of AMKL. In addition, tetrandrine inhibited the growth of the K562 tumours.
Impressively, the ATG7-KO K562 tumours grew much faster than the K562 tumours ( Figure 8C ), which further suggests that the autophagy-related gene ATG7 is a tumour suppressor in leukaemia cells.
Collectively, both the in vitro and in vivo results in our study demonstrate that tetrandrine has significant antileukaemia effects, as it inhibited cell proliferation and induced autophagy-mediated megakaryocyte differentiation. The potential underlying molecular mechanisms involved in these effects of tetrandrine are stimulation of ROSdependent Notch1 and Akt signalling. Thus, our findings provide a novel chemotherapeutic strategy for AMKL and specifically indicate that tetrandrine has the potential to be developed as a differentiation-inducing agent for AMKL chemotherapy.
Figure 7
Tetrandrine 2μΜ has no apparent toxicity in healthy haematopoietic stem cells. The data are representative of the values from at least five independent experiments and are presented as mean±SD; significance was determined using t-tests (*P <0.05). (A) Cell viability of mouse healthy haematopoietic stem cells was assessed by MTS assay. (B) Autophagy was analysed by acridine orange staining assays, and the bright orangered fluorescence of the acidic autophagic vacuoles was observed under a fluorescent microscope and a flow cytometre. Western blot analysis of the levels of the autophagy-related protein LC3 and p62 in mouse healthy haematopoietic stem cells following treatment with DMSO or tetrandrine (2 μM) for 24h. (C) The expression of CD41 in the mouse healthy haematopoietic stem cells was measured by flow cytometry after the cells has been treated with DMSO or 2 μM tetrandrine for 4 days.
Figure 8
Tetrandrine prolongs the survival of the 6133 mouse megakaryoblastic leukaemia model and repressed the growth of the K562 tumour xenografts in athymic nude mice. The data are representative of the values from at least five independent experiments and are presented as mean ±SD; significance was determined using t-tests (*P < 0.05). 
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https://doi.org/10.1111/bph.14031 Figure S1 Tetrandrine facilitates the megakaryocytic differentiation of leukaemia cells. The data are representative of the values from at least five independent experiments and are represented as ±SD; significance was determined using t tests (*P < 0.05, **P < 0.01, ***P < 0.001). The K562 cells were pretreated with 15 μM chloroquine for 1 h, and then treated with DMSO or 2 μM tetrandrine for 72 h. Cellular viability was determined by the trypan blue-exclusion assay, (E) apoptosis was detected by flow cytometry, and the PARP and caspase-3 levels were analysed by western blotting. (F) The K562 and ATG7-knockout K562 cells were treated with DMSO or 2 μM tetrandrine for 24 h and then stained with Annexin V-FITC and PI and analysed by flow cytometry to detect the apoptotic cells. Figure S3 Intracellular ROS production is involved in the tetrandrine-induced effects on cellular proliferation, autophagy and differentiation. The data are representative of the values from at least five independent experiments and are represented as ±SD; significance was determined using t tests (*P < 0.05, **P < 0.01). (A) After a 1 h preincubation with 5 mM Tiron and a 24 h treatment with DMSO or 2 μM tetrandrine, the intracellular ROS levels in the leukaemia cells were measured by flow cytometry. (B) Autophagy was detected by acridine orange staining assays after the cells had been preincubated with 10 mM NAC for 1 h and then treated with DMSO or 2 μM tetrandrine for 24 h. (C) CD41 expression in the leukaemia cells was measured by flow cytometry after a 1 h preincubation with 5 mM Tiron and 4 days of treatment with DMSO or 2 μM tetrandrine. (D) Western blot analysis of the p27 levels in the leukaemia cells after a 1 h pretreatment with 10 mM NAC and then a 24 h treatment with DMSO or 2 μM tetrandrine. (E) After a 24 h treatment with DMSO or 2 μM tetrandrine, the ATG7-knockout K562 cells were stained with 2-NBDG to detect the glucose uptake levels by flow cytometry. (F) After a 24 h treatment with DMSO or 2 μM tetrandrine, the ATG7-knockout K562 cells were stained with Rho123 to detect the mitochondrial membrane potential by flow cytometry. Figure S4 Autophagy is an important event in tetrandrineinduced differentiation. The data are representative of the values from at least five independent experiments and are represented as ±SD; significance was determined using t tests (*P < 0.05, **P < 0.01, ***P < 0.001). (A) The ATG7 expression levels in the patient samples from the oncomine database. (B) Acridine orange staining assays to detect autophagy the leukaemia cells that had been preincubated with 1.5 mM 3-MA for 1 h and treated with DMSO or 2 μM tetrandrine for 24 h. (C) Western blot analysis of the levels of the LC3-II and CTSD proteins in the leukaemia cells that had been pretreated with 15 μM chloroquine for 1 h and then treated with DMSO or 2 μM tetrandrine for 24 h and (D) The CD41 levels in the cells were detected by flow cytometry after a 4 days treatment. (E) Four kinds of different ATG7-knockout K562 cell lines were established using the CRISPR/Cas9 system, according to a standard protocol. (F) Autophagy was detected in the ATG7-knockout K562 cells treated with DMSO or 2 μM tetrandrine for 24 h by labelling with acridine orange. (G) The morphology of the Wright-Giemsa-stained WT and ATG7-knockout K562 cells were observed under a microscope. (H) After being treated with DMSO or 2 μM tetrandrine for 24, 48, and 72 h, the number of WT and ATG7-knockout K562 cells was counted to assess the effect on proliferation. Figure S5 The activation of Notch1 signalling is involved in tetrandrine-induced proliferation inhibition, autophagy and differentiation of leukaemia cells. The data are representative of the values from at least five independent experiments and are represented as ±SD; significance was determined using t tests (*P < 0.05, **P < 0.01, ***P < 0.001). (A) The Notch1 and HES1 expression levels in the patient samples from the oncomine database. (B) Acridine orange staining assays to detect autophagy in the K562 cells that had been preincubated with 10 μM DAPT for 1 h and then treated with DMSO or 2 μM tetrandrine for 24 h. (C) The relative expression levels of Notch1 and Hes1 in the K562 shNC and K562 shNotch1 cells that had been treated with DMSO or 2 μM tetrandrine for 24 h were measured by RT-PCR. GAPDH was used as a control. (D) Western blot analysis of the levels of the NICD proteins in the cytoplasm and nucleus of the K562 shNC and K562 shNotch1 cells treated with DMSO or 2 μM tetrandrine for 24 h or 10 h. (E) After the K562 shNC and K562 shNotch1 cells were treated with DMSO or 2 μM tetrandrine, western blot analyses of the CD41, p21 and p27 proteins were performed on the samples collected at 4 days and 24 h, respectively. (F) After treatment with DMSO or 2 μM tetrandrine for 24, 48, and 72 h, the number of K562 shNC and K562 shNotch1 cells was counted to assess the effect on proliferation. (G) Western blots analyse the NICD levels in the cells had been preincubated with 5 mM Tiron for 1 h and then treated with DMSO or 2 μM tetrandrine for 24 h. (H) Western blot analysis of the levels of the NICD and HES1 proteins in the K562 cells that had been preincubated with 1.5 mM 3-MA for 1 h and then treated with DMSO or 2 μM tetrandrine for 24 h. Figure S6 The activation of Akt signalling is involved in tetrandrine-induced autophagy and differentiation of leukaemia cells. The data are representative of the values from at least five independent experiments and are represented as ±SD; significance was determined using t tests (*P < 0.05).
(A) Acridine orange staining assays analysed autophagy in the K562 cells that had been preincubated with wortmannin for 1 h and then treated with DMSO or 2 μM tetrandrine for 24 h. (B) After 4 days treatment with DMSO or 2 μM tetrandrine, the levels of the CD41 protein in the K562 Akt-CA cells were assessed by western blotting. (C) After a 1 h preincubation with wortmannin and a 10 h treatment with DMSO or 2 μM tetrandrine, the levels of the p-Akt, T-Akt and LC3-II proteins in the K562 Akt-CA cells were assessed by western blotting and (D) CD41 expression was detected by flow cytometry after 4 days of treatment. Figure S7 2μΜ tetrandrine has no apparent toxicity and megakaryocytic differentiation effects in healthy haematopoietic stem cells. The data are representative of the values from at least five independent experiments and are represented as ±SD; significance was determined using t tests (NS, None sense). (A) Colony formation assays using human cord blood mononuclear cells in methylcellulose culture system (supplemented with 10 ng/mL human IL-3 and 50 ng/mL human stem cell factor, 20 ng/mL GM-CSF) at a density of 1 × 10 5 cells/mL and treated with DMSO or 2 μM tetrandrine for 18 days, colonies were scored. (B) Human cord blood mononuclear cells treated with DMSO or 2 μM tetrandrine for 4 days in differentiation culture system (supplemented with thrombopoietin and 50 ng/mL human stem cell factor), the expression of CD41 measured by flow cytometry.
